Companies / Japan

Astellas Fully Focused On R&D

February 2007 | Company Spotlight

Overview

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Companies / Japan In a possible change to its core growth strategy, leading Japanese drugmaker Takeda could be poised to make another large acquisition. The company - which has estimated cash reserves of more than US$14bn...

November 2006

Astellas Seeks To Preserve Lipitor Deal

Companies / Japan Japanese drugmaker Astellas is seeking a declaratory judgement to confirm that a co-marketing deal with Pfizer, regarding the latter's blockbuster cholesterol-lowering drug Lipitor (atorvastatin), will...

November 2006

More Gloom For Takeda's R&D Pipeline

Companies / Japan Leading Japanese drugmaker Takeda has announced another disappointment regarding its R&D pipeline. Following the discontinuation of development on diabetes compound TAK-654 in September, the company...

November 2006

Weakening Yen To Flatter Astellas

Companies / Japan Third-ranked Japanese drugmaker Astellas has once again changed its profit forecasts, revising earlier projections for the first half of the 2006-07 financial year upwards by 40% to JPY60.6bn (US$510mn)....

October 2006

Daiichi-Sankyo Improves Focus

Companies / Japan Fresh from offloading interests in active pharmaceutical ingredients (APIs) and diagnostics, Japan's Daiichi-Sankyo has divested its animal health business to Novartis for an undisclosed fee. The development...

October 2006